LOG IN
SIGN UP
MARKET
ILMN
ILMN
Illumina Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
258.06
+14.49
+5.95%
After Hours: 259.23 +1.17 +0.45% 19:38 05/27 EDT
OPEN
245.88
PREV CLOSE
243.57
HIGH
258.07
LOW
244.43
VOLUME
1.22M
TURNOVER
0
52 WEEK HIGH
526.00
52 WEEK LOW
208.35
MARKET CAP
40.54B
P/E (TTM)
56.29
1D
5D
1M
3M
1Y
5Y
EU court to rule July 13 on Illumina challenge of EU review of Grail -sources
reuters.com · 3d ago
Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI
Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.
Zacks · 3d ago
Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger
Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.
Zacks · 4d ago
Illumina Ventures Announces Promotion and Additions to its Investment Team
FOSTER CITY, Calif., May 24, 2022--Illumina Ventures promotes Malek Faham to Chief Scientist, and adds Charles Lin as Principal and Dave Johnson as Entrepreneur in Residence.
Business Wire · 4d ago
Illumina's TruSight test adds companion diagnostic use for Bayer's cancer drug Vitrakvi
Illumina (NASDAQ:ILMN) said it added a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) comprehensive (EU) test. The company said the CDx pan-cancer indication enables targeted therapy with
Seekingalpha · 4d ago
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. Th...
PR Newswire · 4d ago
These 20 stocks saw the biggest plunges during earnings season
Twenty large-cap stocks saw double-digit declines after issuing results for Q1, according to Bespoke Investment Group. "Earnings season is over, and all we can say is good riddance," Bespoke said.
Seekingalpha · 05/20 15:22
Illumina Employees Volunteer Their Time at Over 100 Events in Celebration of Global Volunteer Month
Illumina strives to create a purpose-driven culture with opportunities for employees to volunteer in their community through organizations that matter most to them. Each year, employees at Illumina...
News Direct · 05/20 14:03
No Data
Learn about the latest financial forecast of ILMN. Analyze the recent business situations of Illumina Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 19 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
15.79%Strong Buy
10.53%Buy
68.42%Hold
5.26%Under-perform
0.00%Sell
Analyst Price Target
The average ILMN stock price target is 358.56 with a high estimate of 520.00 and a low estimate of 249.00.
Current 258.06
EPS
Actual
Estimate
0.470.941.401.87
Institutional Holdings
Institutions: 1.38K
Institutional Holdings: 145.46M
% Owned: 92.59%
Shares Outstanding: 157.10M
TypeInstitutionsShares
Increased
425
8.94M
New
116
913.46K
Decreased
335
3.99M
Sold Out
121
3.72M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+3.80%
Healthcare Equipment & Supplies
+2.75%
Key Executives
Non-Executive Chairman/Independent Director
John Thompson
President/Chief Executive Officer/Director
Francis deSouza
Chief Financial Officer
Sam Samad
Chief Human Resource Officer
Aimee Hoyt
Chief Technology Officer
Alex Aravanis
Chief Information Officer
Carissa Rollins
Chief Marketing Officer
Kathryne Reeves
General Counsel/Secretary
Charles Dadswell
Other
Phillip Febbo
Other
Joydeep Goswami
Other
Kevin Pegels
Other
Susan Tousi
Independent Director
Frances Arnold
Independent Director
Caroline Dorsa
Independent Director
Robert Epstein
Independent Director
Scott Gottlieb
Independent Director
Gary Guthart
Independent Director
Philip Schiller
Independent Director
Susan Siegel
No Data
No Data
About ILMN
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
Webull offers kinds of Illumina, Inc. stock information, including NASDAQ:ILMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ILMN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ILMN stock methods without spending real money on the virtual paper trading platform.